Compare Fox Corp Class B (FOX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs State Street SPDR S&P Biotech ETF — how do they compare? Fox Corp Class B trades at $55.42 (market cap $25.05B), while State Street SPDR S&P Biotech ETF trades at $158.23. The key difference: Fox Corp Class B pays a 1.03% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Fox Corp Class B nearer its low. Which is the better fit depends on your goals.
| FOX | XBI | |
|---|---|---|
Market Cap | $25.05B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $67.76 | $164.28 |
52-Week Low | $44.39 | $86.92 |
Enterprise Value | $28.41B | — |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX stock trades at $57.03, up 3.0% in 24 hours, reflecting strong momentum. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 underscore robust performance, with revenue reaching $16.30 billion in 2025. Technical indicators signal bullish trends, supported by moving averages, while RSI levels suggest potential overbought conditions. The company maintains solid profitability with a net income margin of 9.84% and ROE of 14.29%, though valuation metrics like P/E of 14.84 appear reasonable relative to peers.
Outlook remains positive driven by ad demand and digital growth, including Tubi and FOX One initiatives. Risks include reliance on advertising cycles and competitive pressures. Analyst consensus leans neutral with 42.86% buy ratings, but recent news highlights operational strength. Investors should weigh earnings consistency against market volatility and sector headwinds.
XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.
Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
